Sudeep Pharma Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹12,761 Cr
- P/E
- 69.88
- ROE
- 25.17%
- PEG
- 1.74
- Price to sales
- 18.89
- Debt to equity
- 0.17
- 52W high / low
- ₹1,344 / ₹530
- Sales growth (5Y)
- 24.45%
- EBITDA margin
- 34.48%
- Net profit margin
- 27.14%
- Promoter holding
- 76.16%
- Sales (last year)
- ₹676 Cr
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.[1]
Guidance scorecard · Q2 FY27 call
What Sudeep Pharma Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY27 call
20–40%- Pharma, Food & Nutrition (PFN) segment expects sustained growth, driven mainly by volume expansion, especially phosphates; price increases to reflect more from Q2 onwards.
- Bisglycinate portfolio projected to grow significantly over the next 2-3 years, potentially becoming a top revenue contributor.
- Specialty ingredients business aims to return to historical growth trajectory from Q2 onward after LPG-related supply constraints.
- NSS segment anticipates gradual recovery with single-digit growth in FY’27; expects margin improvement and growth in FY’28 through market diversification and operational improvements.
2 more points from Sudeep Pharma Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what Sudeep Pharma Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- Construction of Sudeep Advanced Materials' Phase 1 is on schedule, targeting commissioning by April 2027.
- Deliveries of major long-lead equipment expected to be completed by October 2026, with ongoing statutory approvals.
- Planning for Phase 2 and Phase 3 expansions is underway, aiming to increase capacity to 100 KTPA.
- Early evaluation started for a further expansion from 100 KTPA to 200 KTPA, pending binding off-take agreements expected later this year.
- Greenfield facility for pharma, food, and nutrition is undergoing regulatory approvals, expected to start supplies from Q3 2026.
- Investments have been made in strengthening the international sales team and expanding capacity with a new greenfield plant commissioning in Q3 2026.
2 more points from Sudeep Pharma Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
See what Sudeep Pharma Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
Rising- Currently, 21 customers are at the laboratory validation stage.
- 16 customers have progressed to pilot-scale evaluation.
- 7 customers have completed pre-commercial or commercial validation and are engaged in active off-take discussions.
- The company expects to conclude two significant binding off-take agreements later this year.
2 more points from Sudeep Pharma Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Sudeep Pharma Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Sudeep Pharma Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Sudeep Pharma Ltd
Shareholding breakup across reporting periods.
| Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|
| Promoters + | 76.16% | 76.16% | 76.16% | 76.16% |
| FIIs + | 1.67% | 1.55% | 1.81% | 2.93% |
| DIIs + | 17.59% | 18.11% | 15.64% | 14.06% |
| Public + | 4.57% | 4.18% | 6.39% | 6.87% |
| No. of Shareholders | 43,599 | 36,503 | 35,695 | 40,465 |
Financials of Sudeep Pharma Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 149 | 116 | 158 | 125 | 163 | 172 | 182 | 158 | 197 |
| Expenses + | 85 | 76 | 99 | 81 | 107 | 112 | 120 | 103 | 123 |
| Operating Profit | 63 | 39 | 59 | 44 | 55 | 60 | 63 | 55 | 73 |
| OPM % | 43% | 34% | 37% | 35% | 34% | 35% | 34% | 35% | 37% |
| Other Income + | 2 | 2 | 4 | 5 | 10 | 7 | 6 | 5 | 6 |
| Interest | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 3 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 5 |
| Profit before tax | 62 | 38 | 58 | 44 | 60 | 62 | 63 | 54 | 71 |
| Tax % | 21% | 24% | 24% | 29% | 21% | 23% | 23% | 25% | 27% |
| Net Profit + | 49 | 29 | 44 | 31 | 47 | 48 | 49 | 41 | 52 |
| EPS in Rs | 5.80 | 2.95 | 4.54 | 3.17 | 4.71 | 4.20 | 4.33 | 3.59 | 4.56 |
Financials of Sudeep Pharma Ltd
Profit & Loss
Annual income statement trend
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 123 | 215 | 343 | 429 | 459 | 502 | 642 | 710 |
| Expenses + | 98 | 171 | 276 | 338 | 276 | 310 | 419 | 459 |
| Operating Profit | 25 | 44 | 67 | 90 | 183 | 192 | 223 | 251 |
| OPM % | 21% | 20% | 20% | 21% | 40% | 38% | 35% | 35% |
| Other Income + | 3 | 3 | 7 | 9 | 6 | 9 | 28 | 25 |
| Interest | 1 | 1 | 2 | 6 | 5 | 7 | 8 | 8 |
| Depreciation | 3 | 4 | 5 | 8 | 9 | 11 | 15 | 17 |
| Profit before tax | 25 | 43 | 69 | 86 | 175 | 183 | 228 | 250 |
| Tax % | 27% | 22% | 27% | 28% | 24% | 24% | 24% | |
| Net Profit + | 18 | 33 | 50 | 62 | 133 | 139 | 174 | 189 |
| EPS in Rs | 2.15 | 3.97 | 5.97 | 7.42 | 15.86 | 14.27 | 15.31 | 16.68 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% |
Financials of Sudeep Pharma Ltd
Balance Sheet
Capital structure and asset base
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 1 | 10 | 11 | 11 |
| Reserves | 80 | 113 | 162 | 222 | 355 | 481 | 872 | 946 |
| Borrowings + | 20 | 31 | 84 | 83 | 78 | 140 | 150 | 189 |
| Other Liabilities + | 30 | 67 | 97 | 113 | 80 | 86 | 141 | 182 |
| Total Liabilities | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 | 1,329 |
| Fixed Assets + | 60 | 68 | 137 | 158 | 180 | 189 | 337 | 524 |
| CWIP | 8 | 24 | 8 | 26 | 45 | 88 | 185 | 54 |
| Investments | 6 | 19 | -0 | 3 | 0 | 0 | -0 | -0 |
| Other Assets + | 57 | 102 | 199 | 232 | 289 | 439 | 652 | 751 |
| Total Assets | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 | 1,329 |
Financials of Sudeep Pharma Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 10 | 35 | -3 | 48 | 66 | 49 | 70 |
| Cash from Investing Activity + | -22 | -40 | -38 | -50 | -49 | -79 | -327 |
| Cash from Financing Activity + | 12 | 13 | 51 | -10 | -13 | 53 | 247 |
| Net Cash Flow | -0 | 8 | 10 | -11 | 4 | 23 | -10 |
| Free Cash Flow | 1 | 24 | -77 | 1 | 13 | -15 | -49 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 62% | 104% | 22% | 78% | 60% | 47% | 56% |
Financials of Sudeep Pharma Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 90 | 94 | 114 | 80 | 115 | 135 | 129 |
| Inventory Days | 77 | 79 | 104 | 142 | 147 | 309 | 356 |
| Days Payable | 70 | 79 | 76 | 77 | 112 | 145 | 113 |
| Cash Conversion Cycle | 97 | 93 | 142 | 145 | 150 | 298 | 372 |
| Working Capital Days | 46 | 13 | 30 | 92 | 99 | 144 | 175 |
| ROCE % | 36% | 36% | 33% | 49% | 36% | 28% |
Guidance history
How Sudeep Pharma Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 20–40% | Flat | Planned | — | Rising |
| Q4 FY26 call → | 10–20% | Flat | Planned | — | Rising |
| Q3 FY26 call → | 20–40% | Flat | Planned | — | Rising |
| Q2 FY26 call → | 20–40% | Flat | Planned | Planned | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Continue your research
What Sudeep Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY